Date: 05th August, 2026

To,
Listing Department,
National Stock Exchange of India Limited
Exchange Plaza, Plot No C-1, Block G, Bandra Kurla Complex,
Bandra (E), Mumbai – 400051

NSE Symbol: BALAXI

Dear Sir/Madam,

Subject: Outcome of Board Meeting

In reference to our letter dated 26th July, 2026, we wish to inform you that the Board of Directors at their meeting held today i.e., on 05th August, 2026, have *inter-alia,* approved the following:

1. **Standalone and Consolidated Unaudited Financial Results of the Company for the quarter ended 30th June, 2026.**
   Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith a copy of the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter ended 30th June, 2026, accompanied by Limited Review Report thereon by the Statutory Auditors of the Company as **Annexure A & Annexure B** respectively.

2. **Took Note of the Progress of the Company's First Pharmaceutical Formulation Plant at Jadcherla, Hyderabad:**
   The Board of Directors took note of the progress of the Company's first pharmaceutical formulation manufacturing facility at Jadcherla, Hyderabad, as apprised by the Managing Director.
   The Board noted that the Company has successfully commenced **commercial production** at the facility with its initial two products, Paracetamol Tablets 500mg and Piroxicam Capsules 20mg, marking the beginning of commercial manufacturing operations.
   The Board further noted that the Company has received **manufacturing product permissions for an additional 29 products**, taking the total approved commercial product portfolio to **31 products**. Raw materials and key input materials for these products have started arriving at the facility, and commercial production will be initiated progressively in line with market requirements. The Company continues to pursue approvals for additional products and will further expand its manufacturing product portfolio in a phased manner.

The Board was also apprised that the **WHO-GMP audit** of the facility was conducted during July 2026 through a joint inspection by CDSCO and the State FDA. The **audit observation report** has been received, and the Company has submitted its **CAPA response** to the regulatory authorities for their review. The Company is on track for obtaining WHO-GMP certification which will further strengthen its manufacturing credentials and support future growth opportunities.

The Board expressed satisfaction with the progress achieved and noted that the Company continues to make steady progress in expanding its manufacturing operations and product portfolio, reinforcing its long-term growth strategy.

The Board meeting commenced at 12.40 P.M. (IST) and concluded at 1.30 P.M. (IST).

The aforesaid information is also being hosted on the Company's website at www.balaxipharma.in.

This is for your information and records.

Thanking You.

Yours faithfully,
For ***Balaxi Pharmaceuticals Limited***

AMAN PUROHIT
Digitally signed by AMAN PUROHIT
Date: 2026.08.05 13:40:14 +05'30'

Aman Purohit
(Company Secretary and Compliance Officer)
ICSI Membership No.: A59345

Encl: As above

ANNEXURE - A

Balaxi Pharmaceuticals Limited

2nd Floor, MAPS Towers, Plot no. 409, Road no. 81, Jubilee Hills, Phase III, Hyderabad-500096, Telangana
CIN:L25191TG1942PLC121598

Unaudited Standalone Financial Results for the Quarter Ended 30th June, 2026

Rs.in lakhs

Particulars	Quarter Ended			Year Ended
	30.06.2026	31.03.2026	30.06.2025	31.03.2026
	(Unaudited)	(Audited)	(Unaudited)	(Audited)
Income				
Revenue from operations	1,558.37	2,023.96	1,670.82	8,085.11
Other income	91.62	336.69	46.22	966.72
Total Income	**1,649.99**	**2,360.65**	**1,717.04**	**9,051.83**
Expenses				
Cost of Goods Sold	1,336.27	1,741.63	1,417.59	6,911.42
Employee benefit expense	186.61	229.46	131.35	599.84
Finance cost	44.65	70.72	63.10	269.63
Depreciation and amortisation expense	59.20	31.29	11.28	70.21
Administrative expenses	134.91	245.99	67.89	497.47
Total Expenses	**1,761.64**	**2,319.29**	**1,691.21**	**8,348.56**
Profit/(loss) before tax and other comprehensive income	**(111.65)**	**41.35**	**25.83**	**703.28**
Tax expenses				
Current tax	-	(20.96)	8.12	145.12
Deferred tax	13.67	46.51	(1.78)	43.47
Net Profit/(loss) for the period	**(125.32)**	**15.80**	**19.49**	**514.68**
Other comprehensive income				
A (i) Items that will not be reclassified to profit or loss in subsequent period	-	-	-	-
Re-measured gains on defined benefit plans		-	-	-
(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-
B (i) Items that will be reclassified to profit or loss	-	-	-	-
(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-
Total comprehensive income for the year	**(125.32)**	**15.80**	**19.49**	**514.68**
Paid up equity share capital - Face value of Rs.2 each	**1,104.15**	**1,104.15**	**1,104.15**	**1,104.15**
Other Equity				
Earnings Per Share (EPS)				
(EPS for the quarter is not annualised)				
-Basic (Amount in Rs.)	(0.23)	0.03	0.04	0.93
-Diluted (Amount in Rs.)	(0.23)	0.03	0.04	0.93

Notes :

1. The un-audited Financial Results for the Quarter ended **30th June, 2026** have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 5th August, 2026. The Financial Results are prepared in accordance with the Indian Accounting Standards (Ind AS) as prescribed under Section 133 of the Companies Act, 2013.

2. Previous period figures have been regrouped, re-arranged and re-classified wherever necessary to conform to current period's classification.

3. The operating segment of the Group is identified as "Specialized Wholesale" as the Chief Operating Decision Maker reviews business performance at an overall level as one segment. Therefore, the disclosure as per Regulation 33 (1)(e) read with Clause L of Schedule IV of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 is not applicable to the Company.

BALAXI PHARMACEUTICALS LIMITED ★ Hyderabad

For and on behalf of Board of Directors
of Balaxi Pharmaceuticals Limited

Ashish Maheshwari
Managing Director
DIN: 01575984

Place: Hyderabad
Date: 5th August, 2026

P. MURALI & CO.,
CHARTERED ACCOUNTANTS
6-3-655/2/3, SOMAJIGUDA,
HYDERABAD - 500 082. T.G, INDIA

Tel. : (91-40) 2332 6666, 2331 2554
(91-40) 2339 3967,
(91-40) 2332 2119, 2331 7032

Email : pmurali.co@gmail.com
pmurali.tax@gmail.com
info@pmurali.com
Website : www.pmurali.com

Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review report to
The Board of Directors
Balaxi Pharmaceuticals Limited

We have reviewed the accompanying statement of unaudited standalone financial results of **BALAXI PHARMACEUTICALS LIMITED** (the "Company") for the quarter ended June 30, 2026 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, 'Interim Financial Reporting, ('Ind AS 34,') prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a report on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

P. MURALI & CO. Hyderabad Chartered Accountants

P. MURALI & CO.,
CHARTERED ACCOUNTANTS
6-3-655/2/3, SOMAJIGUDA,
HYDERABAD - 500 082. T.G, INDIA

Tel. : (91-40) 2332 6666, 2331 2554
(91-40) 2339 3967,
(91-40) 2332 2119, 2331 7032

Email : pmurali.co@gmail.com
pmurali.tax@gmail.com
info@pmurali.com
Website : www.pmurali.com

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Ind AS 34 prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For P. Murali& Co.
Chartered Accountants
FRN: 007257S

P. MURALI & CO., Hyderabad, Chartered Accountants

A. Krishna Rao
Partner
M.No. 020085
UDIN: 26020085DJQGKC4254

Place: Hyderabad
Date: 05-08-2026

ANNEXURE - B

Balaxi Pharmaceuticals Limited

2nd Floor, MAPS Towers, Plot no. 409, Road no. 81, Jubilee Hills, Phase III, Hyderabad-500096, Telangana
CIN:L25191TG1942PLC121598

Unaudited Consolidated Financial Results for the Quarter Ended 30th June, 2026

Rs.in lakhs

Particulars	Quarter Ended			Year Ended
	30.06.2026 (Unaudited)	31.3.2026 Audited	30.6.2025 (Unaudited)	31.03.2026 (Audited)
Income				
Revenue from operations	8,068.18	7,071.37	7,074.21	27,017.35
Other income	(99.21)	291.73	(177.66)	282.12
Total Income	**7,968.97**	**7,363.10**	**6,896.55**	**27,299.47**
Expenses				
Cost of Goods Sold	4,317.37	4,055.08	3,955.99	15,087.53
Employee benefit expense	1,135.89	1,063.23	841.23	3,819.12
Finance cost	73.26	98.99	100.61	390.39
Depreciation and amortisation expense	84.85	64.65	46.25	215.29
Administrative Expenses	2,148.67	1,940.88	1,862.15	7,257.88
Total Expenses	**7,760.04**	**7,222.84**	**6,806.21**	**26,770.21**
Profit /(Loss) Before Exceptional Item	**208.92**	**140.26**	**90.34**	**529.26**
Exceptional Item	-		-	
Profit/(loss) before tax and other comprehensive income	**208.92**	**140.26**	**90.34**	**529.26**
Tax expenses				
Current tax	65.51	32.47	63.11	344.10
Deferred tax	13.67	46.51	(1.78)	43.47
Net Profit/(loss) for the period	**129.74**	**61.28**	**29.01**	**141.69**
Other comprehensive income				
A (i) Items that will not be reclassified to profit or loss in subsequent period				
Exchange differences on translation of foreign operations	274.44	844.12	108.27	1,592.31
(ii) Income tax relating to items that will not be reclassified to profit or loss				
B (i) Items that will be reclassified to profit or loss		-		
(ii) Income tax relating to items that will be reclassified to profit or loss	s	-		
Total comprehensive income for the year	**404.18**	**905.40**	**137.28**	**1,734.00**
Paid up equity share capital - Face value of Rs.2 each	**1,104.15**	**1,104.15**	**1,104.15**	**1,104.15**
Other Equity				
Earnings Per Share (EPS)				
(EPS for the quarter is not annualised)				
-Basic (Amount in Rs.)	0.24	0.11	0.05	0.26
-Diluted (Amount in Rs.)	0.24	0.11	0.05	0.26

Notes :

1. The Unaudited Consolidated Financial Results for the Quarter ended 30th June,2026 have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 5th August, 2026. The Consolidated Financial Results are prepared in accordance with the Indian Accounting Standards (Ind AS) as prescribed under Section 133 of the Companies Act, 2013.

2. Previous period figures have been regrouped, re-arranged and re-classified wherever necessary to conform to current period's classification.

3. The operating segment of the Group is identified as "Specialized Wholesale" as the Chief Operating Decision Maker reviews business performance at an overall level as one segment. Therefore, the disclosure as per Regulation 33 (1)(e) read with Clause L of Schedule IV of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 is not applicable to the Company.

BALAXI PHARMACEUTICALS LIMITED
Hyderabad

For and on behalf of Board of Directors
of Balaxi Pharmaceuticals Limited

Ashish Maheshwari
Managing Director
DIN: 01575984

Place: Hyderabad
Date: 5th August, 2026

P. MURALI & CO.,
CHARTERED ACCOUNTANTS
6-3-655/2/3, SOMAJIGUDA,
HYDERABAD - 500 082. T.G, INDIA

Tel. : (91-40) 2332 6666, 2331 2554
(91-40) 2339 3967,
(91-40) 2332 2119, 2331 7032

Email : pmurali.co@gmail.com
pmurali.tax@gmail.com
info@pmurali.com
Website : www.pmurali.com

Independent Auditor's Review Report on the Quarterly Unaudited Consolidated Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015, as amended

Review report to
The Board of Directors
Balaxi Pharmaceuticals Limited

We have reviewed the accompanying statement of unaudited consolidated financial results of **BALAXI PHARMACEUTICALS LIMITED** (the "Holding Company") and its subsidiaries (the Holding Company and its subsidiaries together referred to as "the Group"), for the quarter ended June 30, 2026 (the "Statement") attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, 'Interim Financial Reporting, ("Ind AS 34") prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

P. MURALI & CO., Hyderabad, Chartered Accountants

P. MURALI & CO.,
CHARTERED ACCOUNTANTS
6-3-655/2/3, SOMAJIGUDA,
HYDERABAD - 500 082. T.G, INDIA

Tel. : (91-40) 2332 6666, 2331 2554
(91-40) 2339 3967,
(91-40) 2332 2119, 2331 7032

Email : pmurali.co@gmail.com
pmurali.tax@gmail.com
info@pmurali.com
Website : www.pmurali.com

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

The Statement includes the results of the following entities:

i. M/s. Balaxi Global FZCO, Dubai (Wholly owned subsidiary) which includes following wholly owned Subsidiaries:

1 Balaxi Healthcare Guatemala, S.A, Dominican Republic(wholly owned subsidiary of Balaxi Global FZCO, Dubai)

2 Balaxi Healthcare Dominican, S.R.L, Dominican Republic(wholly owned subsidiary of Balaxi Global FZCO, Dubai)

3 Balaxi Healthcare, Honduras, S DE RL DE CV(wholly owned subsidiary of Balaxi Global FZCO, Dubai)

4 Balaxi Healthcare El Salvador SA DE (wholly owned subsidiary of Balaxi Global FZCO, Dubai)

5 Balaxi Healthcare Angola(wholly owned subsidiary of Balaxi Global FZCO, Dubai)

6 Balaxi Healthcare Nicaragua (wholly-owned subsidiary of Balaxi Global FZCO, Dubai.)

ii. M/s. Balaxi Healthcare Ecuador S.A.S. (Wholly owned subsidiary)

Based on our review conducted and procedures performed as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

P. MURALI & CO. Hyderabad Chartered Accountants

P. MURALI & CO.,
CHARTERED ACCOUNTANTS
6-3-655/2/3, SOMAJIGUDA,
HYDERABAD - 500 082. T.G, INDIA

Tel. : (91-40) 2332 6666, 2331 2554
(91-40) 2339 3967,
(91-40) 2332 2119, 2331 7032

Email : pmurali.co@gmail.com
pmurali.tax@gmail.com
info@pmurali.com
Website : www.pmurali.com

The accompanying Statement includes unaudited interim financial results and other unaudited financial information in respect of:

Two wholly owned subsidiaries, whose interim financial results and other financial information reflect total revenues of Rs. 7,877.35 Lakhs, total net profit after tax of Rs.206.76 Lakhs and comprehensive income of Rs. 226.50 Lakhs for the quarter ended June 30,2026, as considered in the Statement whose interim financial results and other financial information have not been reviewed by their auditors;

These unaudited interim financial results and other unaudited financial information have been approved and furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the affairs of these subsidiaries is based solely on such unaudited interim financial results and other unaudited financial information.

Our conclusion on the Statement in respect of matters stated above is not modified with respect to our reliance on the financial results certified by the Management

For P. Murali& Co.
Chartered Accountants
FRN: 007257S

P. MURALI & CO., Hyderabad, Chartered Accountants

A. Krishna Rao
Partner
M. No. 020085
UDIN: 26020085EVJQYD6739

Place: Hyderabad
Date: 05-08-2026